SHANGHAI – Hutchison Medipharma Ltd. (Chi-Med) announced its first phase III win with fruquintinib, a targeted VEGFR inhibitor studied as a third-line therapy in 416 Chinese patients with colorectal cancer (CRC). Sharing only top-line results at this time, the FRESCO study met primary and secondary endpoints of improving overall survival and progression-free survival.
SHANGHAI – Hutchison Medipharma Ltd. (Chi-Med) announced its first phase III win with fruquintinib, a targeted VEGFR inhibitor studied as a third-line therapy in 416 Chinese patients with colorectal cancer (CRC).
SHANGHAI – In the midst of a busy news week for CRISPR/Cas9 – a powerful tool that gives cut-and-paste accuracy to gene editing by using adapted immune bacteria – Toolgen Inc. has made advances of its own. The Seoul, South Korea-based company shared encouraging results in Nature Communications in a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.
SHANGHAI – In the midst of a busy news week for CRISPR/Cas9 – a powerful tool that gives cut-and-paste accuracy to gene editing by using adapted immune bacteria – Toolgen Inc. has made advances of its own. The Seoul, South Korea-based company shared encouraging results in Nature Communications in a study evaluating Campylobacter jejuni Cas9 (CjCas9), the smallest Cas9 orthologue characterized to date, for efficient genome editing in vivo.
SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) and its partner, Astrazeneca plc, of London, shared phase II safety and efficacy data for savolitinib in patients with papillary renal cell carcinoma (PRCC), a fatal form of kidney cancer. Presented over the weekend at the Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO) held in Orlando, Fla., the study concluded savolitinib to be generally well-tolerated with antitumor activity in Met-driven PRCC patients.
SHANGHAI – Hutchison China Meditech Ltd. (Chi-Med) and its partner, Astrazeneca plc, of London, shared phase II safety and efficacy data for savolitinib in patients with papillary renal cell carcinoma (PRCC), a fatal form of kidney cancer.
SHANGHAI – Beigene Co. Ltd., of Beijing, is advancing its small-molecule Bruton's tyrosine kinase (BTK) inhibitor candidate, BGB-3111, in a global phase III trial for patients with Waldenström's macroglobulinemia (WM, or lymphoplasmacytic lymphoma), a type of non-Hodgkin lymphoma.
SHANGHAI – Beigene Co. Ltd., of Beijing, is advancing its small-molecule Bruton’s tyrosine kinase (BTK) inhibitor candidate, BGB-3111, in a global phase III trial for patients with Waldenström’s macroglobulinemia (WM, or lymphoplasmacytic lymphoma), a type of non-Hodgkin lymphoma.
SHANGHAI – The Shanghai-based joint venture Wuxi-Medimmune has received the go-ahead to start clinical trials from Chinese regulators for anti-IL-6 antibody WBP216 (MEDI5117) as a therapeutic for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).
SHANGHAI – The Shanghai-based joint venture Wuxi-Medimmune has received the go-ahead to start clinical trials from Chinese regulators for anti-IL-6 antibody WBP216 (MEDI5117) as a therapeutic for autoimmune and inflammatory diseases, in particular rheumatoid arthritis (RA).
